Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Protollin in Early Symptomatic Alzheimer's Disease
NCT07187141Phase 1Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Protollin in Alzheimer's disease (AD) (4 cohorts), sponsored by Brigham and Women's Hospital. Primary endpoint: Safety and tolerability of ascending doses of nasal Protollin at 180 days. Started Nov 2021; status: completed.
02
Drugs
Protollin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07187141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07187141.